Nanobiotix Launches €75M Follow-On Offering to Fuel Cancer Therapy Development
Event summary
- Nanobiotix S.A. launched a €75M global follow-on offering on May 20, 2026, consisting of ADSs in the U.S. and Ordinary Shares/PFW in Europe.
- The offering is led by Jefferies, TD Cowen, and Stifel as global coordinators and joint bookrunners.
- Proceeds will be allocated: <10% to JNJ-1900 (NBTXR3) development, 50-60% to Nanoprimer and other platforms, and 30-40% for general corporate purposes.
- The offering is subject to a 90-day lock-up period for executive and supervisory board members.
- The final amount and pricing will be determined through a book-building process.
The big picture
Nanobiotix's €75M follow-on offering is a strategic move to secure funding for its physics-based cancer therapy platforms. The offering reflects the company's push to expand treatment possibilities for major diseases, aligning with broader industry trends in biotech innovation and capital raising. The scale of the offering and the involvement of major underwriters underscore the significance of this financing round in Nanobiotix's growth trajectory.
What we're watching
- Proceeds Allocation
- How Nanobiotix will balance the allocation of proceeds between JNJ-1900 development, Nanoprimer platform advancement, and general corporate purposes.
- Market Reception
- Whether the market will respond positively to the follow-on offering, given the volatility and liquidity risks highlighted in the press release.
- Execution Risk
- The pace at which Nanobiotix can advance its platforms and meet clinical development milestones with the raised capital.
Related topics